Focus area: Physicians
Efficacy and safety of the combination fluticasone propionate plus salmeterol in asthmatic preschoolers: An observational study
Inhaled corticosteroids (ICS) are the cornerstone of asthma management in pediatric patients. In some cases, asthma is not adequately controlled by ICS alone, so the addition of long-acting beta2-agonists (LABA) is a valid therapeutic strategy therapy. However, their use has rarely been studied in children younger than 5 years.
The aim of this observational study was to evaluate the efficacy and safety of the combination of fluticasone propionate and salmeterol (FP / SA) in asthmatic children under the age of 5 years.
A retrospective study was conducted on 796 children under the age of 5 (2.87 ± 1.22 years, 64.2% males), who were treated with the FP / SA combination. The parameters evaluated by the analysis of the medical records were: hospitalization rates, frequency of wheezing, asthma induced by physical activity, nocturnal wheezing and side effects related to the drug.
The children had previously received short-acting β2-agonists (73%), ICS (17%), montelukast (1%) and ICS with montelukast (2%). The mean duration of FP / SA therapy was 12.45 ± 9.14 months. After adjustment for age, sex and duration of treatment, a reduction of 89% was recorded in annual hospitalization rates (from 27.13% before treatment to 3.01% after FP / SA therapy, p <0.001) , a 71% reduction in the incidence of asthma induced by exercise (36.8% vs after 10.6%, p <0.001), an 81% reduction in nocturnal asthma (33.7% vs later: 6.4%, p <0.001). There were no significant drug-related side effects in the study group.
Combination therapy (FP / SA) is well tolerated and highly effective in asthmatic children under the age of 5 years.
J Asthma. 2018 Jun 29:1-8. doi: 10.1080/02770903.2018.1474923
Hatziagorou E, Kouroukli E, Galogavrou M, Papanikolaou D, Terzi DD, Anagnostopoulou P, Kirvassilis F, Panagiotakos DB, Tsanakas J